Dana-Farber Cancer Institute (Main)

Accepting patients

SL-172154

An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Learn more
  • Phase 1

Accepting patients

TakeAim

TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • IRAK 4 Inhibitor
  • Phase 1/2
  • Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

BXCL701

A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2
Learn more
  • Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
  • Phase 1

Accepting patients

SL-401

Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 1

Accepting patients

AZD6738

A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Learn more
  • Kinase Inhibitor
  • Phase 1

Accepting patients

IS-free Treg Stem Cell Transplant

A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

Venetoclax in Pre- and Post-Transplant Therapy

A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
Learn more
  • Allogeneic Stem Cell Transplant
  • Antimetabolites
  • BCL-2 Inhibitor
  • Chemotherapy
  • Hypomethylating Agents (HMA)
  • Phase 1

Accepting patients

CC-91633 (BMS-986397)

A Phase 1, Open-label, Dose-finding Study of CC-91633 (BMS-986397) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Learn more
  • CELMoD
  • Phase 1

Accepting patients

Venetoclax Basket Trial

A Phase I Study of Venetoclax in Combination With Cytotoxic Chemotherapy, Including Calaspargase Pegol, for Children, Adolescents and Young Adults With High-Risk Hematologic Malignancies
Learn more
  • Antimetabolites
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Steroid
  • Phase 1

Accepting patients

Navitoclax, Venetoclax and Decitabine

A Phase 1 Study of Triplet Therapy With Navitoclax, Venetoclax, and Decitabine for High-risk Myeloid Malignancies
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 1

Filters

Diagnosis

Purpose of Trial

MDS Centers of Excellence

Advanced Filters

Hide Trials

Trial Enrollment Status

Treatment Classifications

Phase